G Aaron Hobbs

16PUBLICATIONS
131CO-AUTHORS
Molecular targetsPredictive and prognostic markersGravimetricsCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Aug 27, 2026
Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

|Jan 20, 2026
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.

Rachel A Burge, Ozgun Le Roux, Olesja Popow

|Nov 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

Szu-Aun Long, Haley Todd, Grace Goodhart

|Oct 24, 2025
PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer.

Rachel A Burge, Lucas Bialousow, Amanda J Linke

|Oct 24, 2025
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.

Mandana Kamgar, G Aaron Hobbes, Raven Davidson

|Sep 15, 2025
Pancreatic Cells Are Resistant to KRASQ61L Expression due to Hyperactive ERK/MAPK Signaling and Apoptosis Induction.

Rachel A Burge, Lucas Bialousow, Thomas McFall

Pageof 3

Frequent Collaborators

8 joint publications

Channing J Der

7 joint publications

Andrew M Waters

5 joint publications

Rachel A Burge

4 joint publications

Craig M Goodwin